Think Again About Cholesterol Survey
|
|
- Della Douglas
- 6 years ago
- Views:
Transcription
1 ATHEROSCLEROSIS SUPPLEMENTS Atherosclerosis Supplements 20 (2015) Think Again About Cholesterol Survey Alberico L. Catapano a, *, Olov Wiklund b, on behalf of the European Atherosclerosis Society a Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, b Sahlgrenska Academy, University of Gothenburg, Abstract Cardiovascular disease (CVD) is still the main cause of death in Europe. Elevated plasma cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), is the main causative risk factor for CVD, most prominently associated with coronary heart disease. A widespread disinformation about cholesterol and CVD is one factor underlying a poor compliance to lipid-lowering therapy. To investigate how cholesterol, CVD and cholesterol reduction is perceived in the population, a survey was commissioned by the European Atherosclerosis Society (EAS). Nearly half of people above 25 years of age are most worried about cancer (45%), compared to just over one in four who are worried about heart disease (27%). A majority believe being overweight (72%), blood pressure (70%) and smoking (67%) most affect heart health, far more than note cholesterol (59%) and family history (39%). The majority of adults recognize that high LDL (or bad ) cholesterol should be a health priority for everyone, including those younger than 40 and those who are not overweight. However, 1 in 4 (25%) incorrectly believe that it does not need to be a concern until someone shows signs or symptoms. Although 89% of adults surveyed agreed it is important for people to know whether or not they have high LDL-C, an overwhelming 92% did not know their LDL-C levels or had never had their cholesterol levels tested. A high 63% had never heard of familial hypercholesterolemia: France had the lowest level of awareness (41%) to with a high 80%, and the association of the disease with high levels of LDL-C is quite poor (only ), with only at 22% versus a high in Spain of 54%. A large part of the people participating in the survey were quite uncertain about the modality of transmission for familial hypercholesterolemia in the family. All in all, this survey highlights the need for more information among citizens for the role of cholesterol in determining CVD Elsevier Ireland Ltd. All rights reserved. Keywords: Cholesterol; hypercholesterolemia; familial; low-density lipoprotein; high-density lipoprotein Introduction Cardiovascular disease (CVD) is still the main cause of death in Europe. Recently published statistics show that more than of deaths among men and about 50% among women are caused by CVD [1]. On the other hand, the mortality from all cancer forms is attributed to of all deaths in men and 19% among women. Among the CVDs, coronary heart disease is the most prominent with about 20% of all deaths. Thus, coronary heart disease is about as common a cause of death as all cancer forms accumulated. Elevated plasma cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), is the main causative risk factor for CVD, most prominently associated with coronary heart disease. The causative relation between cholesterol and CVD has been shown in animal models, in genetic studies, * Corresponding author. Professor Alberico L. Catapano, Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti, 9, Milan,. Tel.: ; fax: address: alberico.catapano@unimi.it (A.L. Catapano). in epidemiological studies [2,3] and in recent decades in a large number of intervention trials [4 7]. Although the scientific evidence is overwhelming, the discussion about the relation between cholesterol and CVD and the benefit from cholesterol lowering is ongoing in the media, driven by poor knowledge about cholesterol. A widespread disinformation about cholesterol and CVD is one factor underlying a poor compliance to lipid-lowering therapy. Even among patients with very high risk or in secondary prevention the compliance to cholesterol lowering therapy is poor [8 10], leaving patients without possible protection against CVD [11]. To investigate how cholesterol, CVD and cholesterol reduction is perceived in the population a survey was commissioned by the European Atherosclerosis Society (EAS). The objectives of the survey were to: Identify adults concern and knowledge about heart health and high cholesterol, on both a personal and a public health level. Uncover areas of misconception of the definition, risk factors, symptoms, and consequences of high LDL-C. Determine adults awareness of familial hyper cholesterolemia Elsevier Ireland Ltd. All rights reserved.
2 2 A.L. Catapano et al. / Atherosclerosis Supplements 20 (2015) 1 5 Table 1 Demographics of the participants in the Think About Cholesterol Survey UK France Spain Norway n 12,142 1,051 1,033 1,006 1,006 1,036 1,001 1, Gender Male 49% 49% 47% 49% 46% 49% 49% 49% 4 50% 49% 4 4 Female 51% 51% 53% 51% 54% 51% 51% 51% 52% 50% 51% 52% 52% Age % 17% 16% 16% % 16% 20% 19% 1 15% % 1 19% 16% 20% 25% 19% 1 19% 21% 1 17% 19% % 21% 20% 22% 22% 22% 20% 21% 21% 19% 19% 19% 17% % 17% % 17% % 17% 19% 17% % 27% 27% 17% 25% 25% 27% 23% % Mean Median Survey methodology The survey was conducted online between 25 th of August and the 9 th of September, 2015, among 12,142 adults, 25 years of age and older. The survey was conducted in eleven European countries (,,, France,,,, Norway, Spain,, and the UK) and in. Sample size in each country was approximately 1,000 (Table 1). The survey was conducted online on behalf of the EAS by Harris Poll, a leading global provider of information and analytics. Respondents to the survey were selected among those who agree to participate in Harris Poll surveys. The study was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Results and discussion Awareness of CVD and cholesterol The results revealed nearly half of people above 25 years of age are most worried about cancer (45%), compared to just over one in four who are worried about heart disease (27%) (Fig. 1). This is in contrast with the published update [1] on causes of death in Europe, showing that CVD causes 40 50% of all deaths while cancer is the cause of death in 25%. A majority believe being overweight (72%), blood pressure (70%) and smoking (67%) most affect heart health, far more than note cholesterol (59%) and family history (39%) (Fig. 3). Only realize that Europe is the region where high cholesterol is most common, 46% mistakenly believe it is North America (Fig. 2). Nearly two-thirds (66%) of respondents do not know LDL-C is the bad type of cholesterol and more than half (54%) do not know having low levels of LDL-C is good for long-term health. The knowledge of cholesterol and CVD evidently can be dramatically improved and this should be a challenge for the medical society. The demand seems to be present since more than four in five (84%) agree that high LDL-C is something that everyone should be very concerned about. Knowledge about cholesterol and causes of high cholesterol The majority of adults recognize that high LDL (or bad ) cholesterol should be a health priority for everyone, including those younger than 40 and those who are not overweight. That said, one in four (25%) incorrectly believe that it does not need to be a concern until someone shows signs or symptoms, and an overwhelming majority (92%) is unaware Diseases or Health Conditions Personally Most Worried About Cancer 45% CVD (NET) Heart Disease Stroke Worried About UK 23% Dementia Heart disease Stroke 27% 27% CVD NET: 37% France 27% 25% 1 17% 39% 22% Spain 43% 25% Diabetes HIV/AIDS Ebola Hepatitis 6% 5% 19% 44% 34% 24% 16% 44% 3 23% Norway 41% 41% 49% 34% None 21% 13% 15% Figure 1. Disease or health conditions that survey participants were personally most worried about. Multiple selections were allowed.
3 A.L. Catapano et al. / Atherosclerosis Supplements 20 (2015) Geographic Region Where High Cholesterol is Most Common Europe 1% 1% 2% 3% 17% 46% UK 2 France North America Europe 23% South America Spain 22% Africa 33% South East Asia Not sure Norway 46% Figure 2. Opinion among participants in which geographic region high cholesterol is most common. Factors that have the Greatest Impact on LDL Cholesterol Levels Weight Diet Cigarette smoking High alcohol intake High blood pressure Family history of heart disease (genetics) Exercise Age Diabetes Medications Gender (male/female) Not sure 2% 13% 1 25% 23% 52% 52% UK France Spain Norway Family History of Heart Disease 44% 17% 34% 42% 24% 13% Figure 3. Survey participants opinion on factors that have the greatest impact on LDL cholesterol levels. Multiple selections were allowed. that women have a higher risk of high bad cholesterol than do men. The majority of adults surveyed (82%) are aware that certain factors (such as diet or weight, etc.) have the greatest impact on LDL-C levels. However, only 52% recognize diet as the major contributor to high cholesterol (Fig. 3), and about one in two adults surveyed make a mistaken connection with the effects of aging and believe incorrectly that high bad cholesterol is a natural consequence of getting older. More than two in five (44%) also incorrectly believe that there are noticeable symptoms associated with bad cholesterol when it reaches high levels (Fig. 4). The survey strongly suggests that improved awareness and knowledge about cholesterol and disease should be a major effort in order to improve cardiovascular health. Very few know their cholesterol levels Although 89% of adults surveyed agreed it is important for people to know whether or not they have high LDL-C, an overwhelming 92% did not know their LDL-C levels or had never had their cholesterol levels tested (Fig. 5). Thus, there is a long gap between knowledge about the risk of high cholesterol and taking action to reduce that risk. The results show that cholesterol testing should be made more easily available for everybody. Lack of correct information More than half of those surveyed feel there is a lack of clear information available on how people should manage their LDL-C (57%). Adults over 40 should aim to keep their LDL-C under mmol/l; however, 59% were unsure of the appropriate target levels. The public discussion about the role of different diets and the differences between guidelines may have given a feeling of poor information and insecurity how to find correct information. There is room for improvement using scientifically based information tools. The public is asking for information and a majority believes that managing high LDL-C with diet is important (89%), but they are lacking correct information.
4 4 A.L. Catapano et al. / Atherosclerosis Supplements 20 (2015) 1 5 Symptoms of High LDL Cholesterol None - there are no symptoms ated with high LDL (or ''bad'') holesterol Not Sure Fatigue Weight eg tgain UK Fran e 20% ty breathing 15% 37% Chest pain 14% Spain Dementia 4% Coughing 3% 45% 3% Norway 41% Not sure 22% 49% 34% 3 Figure 4. Survey participants opinion on symptoms associated with high LDL cholesterol. Multiple selections were allowed. Most Recent Cholesterol Levels LDL cholesterol HDL cholesterol Total cholesterol 7% 10% Mean: 3.5 Median: 3 Mean: 2.3 Median: 2 Mean: 5.2 Median: 5 61% 62% 59% Figure 5. Survey participants self-reported cholesterol levels. Entered a number Not sure/don't recall I have never had my cholesterol levels tested Familial hypercholesterolemia (FH) If we analyze the data regarding the questions related to FH, surprisingly 63% have never heard of it: France had the lowest level of awareness (41%) to with a high 80%, and the association of the disease with high levels of LDL-C is quite poor (only ), with only at 22% vs a high in Spain of 54%. Consequently a large part of the people participating in the survey were quite uncertain about the modality of FH transmission in the offspring with 61% not sure about the likelihood of a child of someone with FH inheriting the condition. All in all, the knowledge about FH appears to be rather poor and there is a clear need to better promote understanding of the disease. However, this cannot be without proper campaigns to the public and, likewise, to physicians led by scientific societies. Limitations The survey was not performed on a random population sample but rather on adults agreeing to participate in online surveys. This should be considered in the interpretation of the results. However, the results give a good general impression of the general awareness of the adult population about the issues raised in the survey, and may be a basis for further discussions and also for future initiatives to improve awareness. Trends for differences between countries were observed; the design of the study and data about specific differences between nations are presented as supplementary material and will be further exploited in subsequent publications. Conclusion The survey indicates that the public is aware of cholesterol as a risk factor and the importance of this risk factor for cardiovascular health. However, there are a number of misconceptions that may interfere with possibilities to reduce heart disease in the population. Although awareness may be high, action is taken by a minority. Improvement in knowledge, in available correct information, and access to blood testing are key factors to improve cardiovascular health by reducing plasma cholesterol.
5 A.L. Catapano et al. / Atherosclerosis Supplements 20 (2015) A complete presentation of the results of the survey is available on Atherosclerosis Supplements as supplementary information. Source of funding and authorship The supplement was financially supported by Sanofi and Regeneron Pharmaceuticals Inc. The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), and were fully responsible for all content development and editorial decisions. Conflict of interest None declared. Appendix A. Supplementary data Supplementary data related to this article can be found at: References 1. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe - epidemiological update Eur Heart J 2015;36(40): Emerging Risk Factors C, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307(23): Prospective Studies C, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370(9602): Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753): Cholesterol Treatment Trialists (CTT) Collaboration, Fulcher J, O Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: metaanalysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385(9976): Cholesterol Treatment Trialists (CTT) Collaboration, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607): Cholesterol Treatment Trialists (CTT) Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380(9841): Annual report SWEDEHEART Scand Cardiovasc J 2014;48 Suppl 63: Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015 pii: [Epub ahead of print] 10. Siggaard-Andersen N, Freiberg JJ, Nordestgaard BG. Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids. Dan Med J 2012;59(7):A Hamood H, Hamood R, Green MS, Almog R. Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality. Pharmacoepidemiol Drug Saf 2015;24(10):
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationthe high CVD risk smoker
Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society
More informationCurrent guidelines on prevention with a focus on dyslipidemias
Review Article Current guidelines on prevention with a focus on dyslipidemias Ian M. Graham 1,2, Alberico L. Catapano 3, Nathan D. Wong 4 1 Trinity College Dublin, Dublin, Ireland; 2 Adelaide Health Foundation,
More informationThe EUROASPIRE surveys: lessons learned in cardiovascular disease prevention
Brief Report The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention Kornelia Kotseva 1,2 ; on behalf of the EUROASPIRE Investigators 1 National Heart & Lung Institute, Imperial College
More informationARIC Manuscript Proposal #2426. PC Reviewed: 9/9/14 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal #2426 PC Reviewed: 9/9/14 Status: A Priority: 2 SC Reviewed: Status: Priority: 1a. Full Title: Statin drug-gene interactions and MI b. Abbreviated Title: CHARGE statin-gene GWAS
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationIJBCP International Journal of Basic & Clinical Pharmacology. Statin therapy and Vitamin D
Print ISSN 2319-2003 Online ISSN 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.18203/2319-2003.ijbcp20151342 Research Article Statin therapy and Vitamin D Arunkumar Radhakrishnan
More informationCARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE
CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or
More informationStatins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK
1 Disclosures Advisory boards PCSK9- Sanofi/ Regeneron, Amgen, Pfizer, Roche, MSD NLI/ SC member for Odyssey- (Sanofi/ Regeneron), Roche Investigator initiated research grant support (Sanofi/Regeneron/
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationLLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.
ESPEN Congress Leipzig 2013 LLL Session - Nutrition support in diabetes and dyslipidemia Dyslipidemia: targeting the management of cardiovascular risk factors M. Leon Sanz (ES) Dyslipidemia: Targeting
More informationPrimary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines
18 MEDICINSKI GLASNIK / str. 18-23 Vojislav Giga 1,2, Marija Petrović 1 Primary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines Abstract: European Society
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk
ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol
More informationTHE CRITICAL ROLE OF NURSES. Helping patients take control of their LDL-C to lower the risk of MI and stroke.
THE CRITICAL ROLE OF NURSES Helping patients take control of their LDL-C to lower the risk of MI and stroke. WHEN IT COMES TO REDUCING PATIENTS HIGH CHOLESTEROL, NURSES PLAY A KEY ROLE Many patients may
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationImaging-Guided Statin Allocation: Seeing Is Believing
Imaging-Guided Statin Allocation: Seeing Is Believing The New Paradigm in Personalized Risk Assessment & Medication Prescribing Presented by: Michael J. Blaha May 15, 2014 1 General Principles of Talk
More informationSecondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationREVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
More informationLIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:
More informationStatins in the elderly: What evidence of their benefit in prevention?
Archives of Cardiovascular Disease (2010) 103, 61 65 SCIENTIFIC EDITORIAL Statins in the elderly: What evidence of their benefit in prevention? Les statines chez les personnes âgées : quelle preuve de
More informationEUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium
EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE
ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE Professor Željko Reiner, MD, PhD,FRCP(Lond), FESC Director, University Hospital Center Zagreb School of Medicine, University of Zagreb,
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationBackground. Magnus Heldal 1 and Terje R. Pedersen 2. 1 Gardermoen Heart Centre,
LDL GOAL ACHIEVEMENT IN CHRONIC CORONARY HEART DISEASE PATIENTS: A COMPARISON BETWEEN USUAL CARE AND A STRUCTURED FOLLOW-UP PROGRAMME IN 766 CONSECUTIVE PATIENTS IN CARDIOLOGY PRACTICE Magnus Heldal 1
More informationInternational Menopause Society comment on press release from the European Heart Journal
International Menopause Society comment on press release from the European Heart Journal Study shows doctors are failing to lower heart patients cholesterol adequately. Women are particularly at risk of
More informationEAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!
Press release 84 th European Atherosclerosis Society Congress, Innsbruck, Austria For circulation 29 th May, 2016. 84 th Annual Congress of the European Atherosclerosis Society (EAS) May 29 th - June 1
More informationA Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.
A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. Brian A. Ference MD, MPhil, MSc, John J. P. Kastelein
More informationFatty acids and cardiovascular health: current evidence and next steps
Fatty acids and cardiovascular health: current evidence and next steps Emanuele Di Angelantonio, MD, PhD Department of Public Health and Primary Care NICE guidelines on fatty acids Eliminate the use of
More informationStatins and Cholesterol. Noreen Devanney Primary Care Pharmacist Surrey Heath CCG
Statins and Cholesterol Noreen Devanney Primary Care Pharmacist Surrey Heath CCG What are Statins? Statins are drugs that lower cholesterol They act on the liver to decrease production Usually act within
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationThis is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy.
Treatment Guideline Statin Prescribing Objective These guidelines represent the views of the Gloucestershire Hospitals NHS Foundation Trust, which were arrived at after consideration of the available evidence
More informationModels of preventive care in clinical practice to achieve 25 by 25
Models of preventive care in clinical practice to achieve 25 by 25 Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLow HDL C and/or elevated triglycerides (TG) was seen in nearly two thirds of MI patients
PRESS RELEASE New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL Cholesterol Surveys establish residual
More informationCleveland Clinic Heart Health Survey
Cleveland Clinic Heart Health Survey Table of Contents Section Slide # Survey Objectives and Methodology 3 Key Findings Part 1: Perceived Heart Health Knowledge 4 Key Findings Part 2: Heart Health Related
More informationPlant sterols/stanols for cholesterol lowering and prevention of cardiovascular disease
Plant sterols/stanols for cholesterol lowering and prevention of cardiovascular disease Prof Dr Elke A. Trautwein, Senior Scientist Cardiovascular Health, Unilever, on behalf of the International Plant
More informationCardiovascular Controversies: Exploring the ACC and AHA Guidelines on the Treatment of Blood Cholesterol
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationRe-assessing the role of non-fasting lipids; a change in perspective
Editorial Page 1 of 5 Re-assessing the role of non-fasting lipids; a change in perspective Zareen Farukhi 1,2, Samia Mora 1,2 1 Center for Lipid Metabolomics, Division of Preventive Medicine, 2 Department
More informationTo: Olten, June 5 th, 2015 / mr1.0. Dear colleagues
To: Prof. N. Rodondi, MD (Member of AGLA, Inselspital Bern), PD Dr. med. Erik von Elm (IUMSP, Centre Hospitalier Universitaire Vaudois, Lausanne) Prof. Dr. med. Christoph Meier (Stadtspital Triemli, Zürich)
More informationFamilial Hypercholesterolemia
Understanding (FH) Familial Hypercholesterolemia For more information, visit Understanding Familial Hypercholesterolemia (FH) Your doctor may have told you that too much of the bad type of cholesterol
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More informationNew Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases
New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases Stanley L. Hazen, MD, PhD. Center for Cardiovascular Diagnostics and Prevention, Lerner Research Institute, Cleveland Clinic,
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationAdverse Effects of Statin Therapy: Perception versus the Evidence
Adverse Effects of Statin Therapy: Perception versus the Evidence Focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract A Consensus Statement from the European
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationNational public health campaigns have attempted
WINTER 2005 PREVENTIVE CARDIOLOGY 11 CLINICAL STUDY Knowledge of Cholesterol Levels and Targets in Patients With Coronary Artery Disease Susan Cheng, MD; 1,2 Judith H. Lichtman, MPH, PhD; 3 Joan M. Amatruda,
More informationTHE BENCHMARK. UNAIDS and the polling company Zogby International surveyed the world on what people think about the AIDS epidemic and response.
THE BENCHMARK UNAIDS and the polling company Zogby International surveyed the world on what people think about the AIDS epidemic and response. THE BENCHMARK UNAIDS and the polling company Zogby International
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists (CTT) Collaborators.
More informationPrimary Prevention of Cardiovascular Disease (CVD) Events with Statins. 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins
Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 2 Welcome by Michael Pignone, MD, MPH Hi, my name is Dr.
More informationHas the science of supplementation reached the breakthrough point?
IADSA Annual Week 19-21 June 2018 The Food Supplement Sector: Evolution and Evaluation Has the science of supplementation reached the breakthrough point? Manfred Eggersdorfer PhD Professor for Healthy
More informationPage 1 of 13. Produced: July 2018 NHS Midlands and Lancashire CSU Not for Commercial Use
New Medicine Recommendation Evolocumab (Repatha SureClick ) For prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin Recommendation: Black Evolocumab is
More informationSection Editor Mason W Freeman, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationNational dementia survey reveals Scots have positive attitudes and improved knowledge
Press Release Embargoed until 21 st September 2018 National dementia survey reveals Scots have positive attitudes and improved knowledge A new Scottish Social Attitudes report, published today for World
More informationEffects of whole grain intake on weight changes, diabetes, and cardiovascular Disease
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown
More informationAchieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care
Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More information!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants
Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationAppendix F Simon Broome Diagnostic criteria for index individuals and relatives
Appendix F Simon Broome Diagnostic criteria for index individuals and relatives 1 SIMON BROOME DIAGNOSTIC CRITERIA FOR INDEX INDIVIDUALS (PROBANDS) 2 2 GENDER- AND AGE-SPECIFIC LDL-C CRITERIA FOR THE DIAGNOSIS
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationTitle: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study.
Manuscript type: Invited Commentary: Title: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study. Authors: David C Wheeler 1 and Bertram
More informationA loss-of-function variant in CETP and risk of CVD in Chinese adults
A loss-of-function variant in CETP and risk of CVD in Chinese adults Professor Zhengming CHEN Nuffield Dept. of Population Health University of Oxford, UK On behalf of the CKB collaborative group (www.ckbiobank.org)
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More information